Publications by authors named "Benjamin Pardo-Yules"
Background: fewer than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after peginterferon alfa/ribavirin (Peg-IFN/RBV) therapy.
Aims: thalidomide posses anti-inflammatory and immunomodulatory properties through inhibition of tumor necrosis factor and costimulatory effect on human CD8+ T cells.
Methods: we started a prospective, open label trial of retreatment of very-difficult-to-treat genotype 1 chronic hepatitis C patients (CHC) patients, who had failed to respond to the (Peg-IFN/RBV), with a triple therapy consisting in these same antivirals plus thalidomide 200 mg/day (the TRITAL study).
Article Synopsis
- Experimental models for studying hepatic encephalopathy (HE) are limited by the challenge of monitoring neuronal function without anesthetics, which confound results.
- The study tested motor-evoked potentials (MEPs) in rat models of acute liver failure (ALF) using cranial and peripheral nerve stimulation, finding abnormal MEPs linked to neurological symptoms in certain conditions.
- The findings suggest that monitoring MEPs in awake rats is an effective way to evaluate HE, highlighting the ineffectiveness of mannitol in preventing neurological function decline associated with ammonia levels.